A new ray of hope in hepatocellular carcinoma space after Stivarga

 In Drug Development, FDA, Pharmaceutical companies

Patients suffering from hepatocellular carcinoma have new ray of hope with Stivarga, recently approved FDA drug for 2nd line treatment after Sorafenib.

There is a growing competition in the Liver cancer space with big pharmaceuticals giants like Eli Lilly, Novartis, Bristol mayer Squibb etc. heading fast. However Stivarga’s approval for HCC promises a prospective future for Bayer with its Sorafenib being already a standard of care for HCC patients.

iPlexusTM – The Intelligence Machine for Life Sciences. Try it now.

By Dr. Esha Pandita
Research Analyst, Science and Research @ Innoplexus

Share this Image On Your Site

Leave a Comment